CAS NO: | 3385-03-3 |
包装 | 价格(元) |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Flunisolide is a corticosteroid, which is an orally activeglucocorticoid receptoractivator withanti-inflammatoryactivity. Flunisolide can induce eosinophilapoptosis, and is used for the research of asthma or rhinitis, and inflammation[1][2]. | ||||||||||||||||
体外研究 (In Vitro) | Flunisolide (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation[1].Flunisolide (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated from mild to moderate asthmatics), and induces sputum eosinophil apoptosis[2].Flunisolide (0.1-10 μM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells[3].Flunisolide (115 μM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent[4]. Apoptosis Analysis[2]
| ||||||||||||||||
体内研究 (In Vivo) | Flunisolide (Intranasal administration, 0.3–10 μg/mouse, daily, from days 21-27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice[1].Flunisolide (Intranasal administration, 0.3–10 μg/mouse, daily, from days 21-27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 434.50 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H31FO6 | ||||||||||||||||
CAS 号 | 3385-03-3 | ||||||||||||||||
中文名称 | 氟尼缩松 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 125 mg/mL(287.69 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|